Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database
BackgroundTemozolomidee (TMZ) is an alkylating antitumor drug used in the treatment of glioblastoma and anaplastic astrocytoma. It is often combined with radiotherapy and has cytotoxic effects on tumor cells. Although temozolomidee has a certain efficacy in the treatment of brain malignancies, its n...
Saved in:
| Main Authors: | Yu Liu, Lan Ma, Xiaojia Fu, Yi Zhang, Jinyu Zheng, Zhongjun Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1578406/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01) -
Analysis and mining of Dupilumab adverse events based on FAERS database
by: Hui Gao, et al.
Published: (2025-03-01) -
Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01) -
A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01) -
Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database
by: Luyao Xu, et al.
Published: (2025-06-01)